Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27).
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Kepler Cheuvreux Upgrades Maire Tecnimont (MT:IM) to Buy
- Jefferies Upgrades Leonardo Spa (LDO:IM) (FINMY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
